Prescription Justice
BLOG POSTS

23
Dec
2019

Prescription Justice President Pens Op Ed for The New York Daily News

The New York Daily News recently published the Op-Ed United we stand, at least on drug prices by Prescription Justice President, Gabriel Levitt. Mr. Levitt’s Op-Ed underscores the fact that while there is little consensus among voters from different political parties, there is one stark exception: prescription drug prices.

12
Sep
2018

Prescription Justice Awards U.S. Senator Elizabeth Warren with 5-Star Rating

U.S. Senator Elizabeth Warren (D-MA) was awarded a 5-Star rating from Prescription Justice for her full support of the Prescription Justice Policy Platform. These are commonsense and necessary policies to lower drug prices here at home and expand access to lower cost medication from pharmacies in other countries.

27
Jun
2018

U.S. Senator Angus King Receives 5-Star Rating From Prescription Justice

We are pleased to announce that U.S. Senator Angus King (I-ME) has received the Prescription Justice 5-star rating based on his full support of the organization’s Policy Platform to lower drug prices here and expand access to safe and affordable medication from other countries. Senator King’s 5-star rating reflects his unwavering support of commonsense policy solutions to end the prescription drug affordability crisis.

19
Jun
2018

Prescription Justice Announces Endorsement of Ryan Watts for U.S. House of Representatives

Prescription Justice has endorsed Ryan Watts for the U.S. House of Representatives in the 6th District of North Carolina based on his pro-patient/pro-consumer stance to address the prescription drug price crisis in America.

16
May
2018

Trump’s Plan Puts Pharma First

Last Friday, President Trump unveiled his blueprint to lower drug prices named American Patients First. Sadly, the Administration’s plan excludes Trump’s campaign promises to use the massive buying power of the government’s Medicare program to negotiate lower prices for older Americans and provide greater access to imported, lower-cost medications.